Table 8.

Results of the sensitivity analysis for the DPP-4 plus metformin vs. metformin mixed treatment comparison meta-analysis: HbA_1c mean change from baseline and patients achieving HbA_1c <7%

Treatment	Weighted mean change in HbA1c (95% CrI)	Weighted mean change in HbA1c (95% CrI) with studies DeFronzo et al. [89] and Bosi et al. [88] removed	Odds ratio of patients achieving HbA1c <7% vs. metformin (95% CrI)	Odds ratio of patients achieving HbA1c <7% vs. metformin (95% CrI) with DeFronzo et al. [89] removed
Alogliptin + metformin	−0.68 (−0.96 to −0.40)*	−0.68 (−0.95 to −0.40)*	6.41 (3.15–11.98)*,†	6.39 (3.19–11.85)*,†
Linagliptin + metformin	−0.57 (−0.75 to −0.40)*	−0.56 (−0.73 to −0.40)*	3.37 (1.91–5.72)*	3.30 (1.89–5.59)*
Saxagliptin + metformin	−0.61 (−0.79 to −0.44)*	−0.57 (−0.76 to −0.37)*	2.17 (1.56–2.95)*,†	1.91 (1.32–2.67)*,†
Sitagliptin + metformin	−0.64 (−0.79 to −0.50)*	−0.63 (−0.77 to −0.48)*	2.87 (2.13–3.82)*	2.79 (2.08–3.71)*
Vildagliptin + metformin	−0.59 (−0.75 to −0.44)*	−0.54 (−0.71 to −0.40)*	2.45 (1.65–3.50)*	2.40 (1.62–3.43)*

CrI credible interval, DPP-4 dipeptidylpeptidase-4, HbA _1c glycosylated hemoglobin

* Statistically significant versus metformin

^† Statistically significant between treatment groups